Intraperitoneal distribution imaging in ovarian cancer patients

作者: S. J. Dawson , R. J. Hicks , V. Johnston , D. Allen , T. Jobling

DOI: 10.1111/J.1445-5994.2009.02112.X

关键词: RadiologyDistribution (pharmacology)SurgeryParacolic guttersPeritoneal dialysisMedicineOvarian cancerPouchPeritoneal cavityPeritoneal fluidCancer

摘要: Background/Aims: Optimal delivery of intraperitoneal (IP) chemotherapy is dependent on adequate drug distribution. An accurate understanding the limitations IP distribution critical if we are to improve cytotoxic through this route. Methods: Using repeated scintigraphic peritoneography investigated peritoneal fluid in patients receiving therapy. Both early (1–6 h) and late (24–48 h) images were performed. The cavity was divided into six regions; pouch Douglas, left right paracolic gutters, subphrenic spaces subhepatic space. each region classified as absent (0), faint (1) or intense (2). A total score calculated from summation values for regions. Distribution then graded according follows: Grade 0 = 0–3; 1 4–6; 2 7–9; 3 10–12. Results: Twenty-six participants included study: all 26 had imaging performed 21 these also imaging. Thirteen (50%) 15 (71%) grade respectively. most common abdominal regions show maldistribution spaces. Conclusions: This study highlights deficiencies following delivery, with majority demonstrating multiple uptake Future large clinical studies investigating should include analyses our optimal route.

参考文章(21)
M. J. Piccart, A. Floquet, G. Scarfone, P. H. B. Willemse, J. Emerich, I. Vergote, L. Giurgea, C. Coens, A. Awada, J. B. Vermorken, Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. International Journal of Gynecological Cancer. ,vol. 13, pp. 196- 203 ,(2003) , 10.1111/J.1525-1438.2003.13360.X
James C. Brandes, Warren J. Packard, Shelly K. Watters, Claire Fritsche, Optimization of dialysate flow and mass transfer during automated peritoneal dialysis American Journal of Kidney Diseases. ,vol. 25, pp. 603- 610 ,(1995) , 10.1016/0272-6386(95)90131-0
Angèle L.M. Oei, Leon F.A.G. Massuger, Wim J.G. Oyen, Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer. Cancer Biotherapy and Radiopharmaceuticals. ,vol. 22, pp. 508- 514 ,(2007) , 10.1089/CBR.2007.358A
S. Makhija, M. Leitao, P. Sabbatini, N. Bellin, L. Almadrones, L. Leon, D.R. Spriggs, R. Barakat, Complications Associated with Intraperitoneal Chemotherapy Catheters Gynecologic Oncology. ,vol. 81, pp. 77- 81 ,(2001) , 10.1006/GYNO.2000.6108
Laurie Elit, Thomas K. Oliver, Allan Covens, Janice Kwon, Michael Fung-Kee Fung, Holger W. Hirte, Amit M. Oza, , Intraperitoneal chemotherapy in the first‐line treatment of women with stage III epithelial ovarian cancer Cancer. ,vol. 109, pp. 692- 702 ,(2007) , 10.1002/CNCR.22466
Joan L. Walker, Deborah K. Armstrong, Helen Q. Huang, Jeffrey Fowler, Kenneth Webster, Robert A. Burger, Daniel Clarke-Pearson, Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study Gynecologic Oncology. ,vol. 100, pp. 27- 32 ,(2006) , 10.1016/J.YGYNO.2005.11.013
Mahesh A. Varia, Frederick B. Stehman, Brian N. Bundy, Jo Ann Benda, Daniel L. Clarke-Pearson, Ronald D. Alvarez, Harry J. Long, Intraperitoneal Radioactive Phosphorus (32P) Versus Observation After Negative Second-Look Laparotomy for Stage III Ovarian Carcinoma: A Randomized Trial of the Gynecologic Oncology Group Journal of Clinical Oncology. ,vol. 21, pp. 2849- 2855 ,(2003) , 10.1200/JCO.2003.11.018
Maurie Markman, Intraperitoneal drug delivery of antineoplastics. Drugs. ,vol. 61, pp. 1057- 1065 ,(2001) , 10.2165/00003495-200161080-00003
Robert C. Young, Mark F. Brady, Roberta K. Nieberg, Harry J. Long, Allan R. Mayer, Samuel S. Lentz, Jean Hurteau, David S. Alberts, Adjuvant Treatment for Early Ovarian Cancer: A Randomized Phase III Trial of Intraperitoneal 32P or Intravenous Cyclophosphamide and Cisplatin—A Gynecologic Oncology Group Study Journal of Clinical Oncology. ,vol. 21, pp. 4350- 4355 ,(2003) , 10.1200/JCO.2003.02.154